Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.

Science translational medicine - 8 Sept 2010

Wallin Jeffrey J, Guan Jane, Prior Wei Wei, Edgar Kyle A, Kassees Robert, Sampath Deepak, Belvin Marcia, Friedman Lori S

Abstract excerpt

The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is frequently disrupted in cancer and implicated in multiple aspects of tumor growth and survival. In addition, increased activity of this pathway in cancer is associated with resistance to chemotherapeutic agents. Therefore, it has been hypothesized that PI3K inhibitors could help to overcome resistance to chemotherapies. We used preclinical cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Indazoles

Share to Neoplasm Transplantation

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Sulfonamides

Source

Identifiers

PMID: 20826841
DOI: 10.1126/scitranslmed.3000630

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.PMID 20826841Read ↗

Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.Semantic proximity Read ↗

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.Semantic proximity Read ↗

AKT in cancer: new molecular insights and advances in drug developmentSemantic proximity Read ↗

The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated ReviewSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.Semantic proximity Read ↗

Targeting PI3K Signaling in Combination Cancer Therapy.Semantic proximity Read ↗

More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.Semantic proximity Read ↗

Exploiting the PI3K/AKT pathway for cancer drug discovery.Semantic proximity Read ↗

A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genesSemantic proximity Read ↗

CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathwaySemantic proximity Read ↗

PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.